NCT03832127

Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients

Exploratory Study Evaluating the Interest of PET to 18F-Fludarabine for the Initial Assessment and End-treatment Evaluation of Patients With Symptomatic Multiple Myeloma in the First Line of Treatment, Not Candidates for Marrow Autograft

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Nantes University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.

Conditions

• Myeloma

Interventions

Type	Name	Description
DRUG	18F-Fludarabine	Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma

Timeline

• Start date: 2022-09-09
• Primary completion: 2024-09-09
• Completion: 2026-09-09
• First posted: 2019-02-06
• Last updated: 2024-06-14

Locations

7 sites across 1 country: France